Direct and Indirect Economic Consequences of Multiple Sclerosis in Ireland
- 17 September 2014
- journal article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 12 (6) , 635-645
Abstract
Multiple sclerosis (MS) has significant financial consequences for healthcare systems, individual patients and households, and the wider society. This study examines the distribution of MS costs and resource utilisation across cost categories and from various perspectives, as MS disability increases. Two hundred and fourteen patients with MS were recruited from a specialist MS outpatient clinic in Ireland and included in an interview-based study on MS-related healthcare resource consumption and costs. Patients were grouped into three categories based on disability: mild [Expanded Disability Status Scale (EDSS) score 0–3.5, n = 114], moderate (EDSS 4.0–6.5, n = 72) and severe (EDSS 7.0–9.5, n = 27). The mean annual direct and indirect costs (in year 2012 values) were estimated using non-parametric bootstrapping. Participants were 66.4 % female, with a mean age of 47.6 years and a mean EDSS score of 3.6. The majority had relapsing-remitting MS (RRMS) (53 %). The mean annual direct (indirect) costs per person were €10,249 (€9,447), €13,045 (€31,806) and €56,528 (€39,440) in mild, moderate and severe MS, respectively. Direct costs are driven by the cost of disease-modifying therapies and professional home help in mild and severe MS, respectively. Between 74 % (severe MS) and 96 % (mild MS) of all direct costs are borne by the healthcare payer, the remainder being incurred by patients, their families or other non-healthcare organisations. MS is associated with high levels of healthcare resource consumption and costs, and these costs increase with increasing disability. There is potential to significantly reduce the economic burden of MS through interventions that prevent progression from mild or moderate MS to severe MS, help support independent living at home and keep people with MS in the work force.Keywords
This publication has 25 references indexed in Scilit:
- Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MSPLOS ONE, 2011
- Cost of multiple sclerosis in the Czech Republic: The COMS studyMultiple Sclerosis Journal, 2011
- Cost-of-Illness StudiesPharmacoEconomics, 2011
- Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotypeJournal of Neurology, Neurosurgery & Psychiatry, 2011
- New perspectives in the natural history of multiple sclerosisNeurology, 2010
- Multiple Sclerosis in the UKPharmacoEconomics, 2008
- Costs and quality of life of patients with multiple sclerosis in EuropeJournal of Neurology, Neurosurgery & Psychiatry, 2006
- GP reimbursement and visiting behaviour in IrelandHealth Economics, 2005
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Rating neurologic impairment in multiple sclerosisNeurology, 1983